Emapalumab

Specification

• Cat#: THA-0114
• Product Name: Emapalumab
• Description: Emapalumab is an interferon gamma blocking antibody used to treat primary hemophagocytic lymphohistiocytosis.
• Sequences: Not Available
• Molecular Weight: 154400.0 Da
• Introduction: Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018. The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy. As well, emapalumab was given the status of PRIME by the EMA.
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: C6430H9898N1718O2038S46
• Appearance: Solid
• Endotoxin Level: < 0.001 EU/μg of the protein by the LAL method

Pharmaceutical Information

• Pharmacodynamics: In phase 2/3 clinical trials, emapalumab administered concomitantly with dexamethasone reported an overall response in 63% of the patients. The overall response was defined as achievement of a complete or partial response or HLH improvement. In this trial and as a proof of interferon-gamma neutralization, there was registered a sharp decrease in serum CXCL9 and to avoid QT prolongation in the presence of low doses of emapalumab.
• Targets: Interferon gamma